Search

Your search keyword '"Bruno Vincenzi"' showing total 427 results

Search Constraints

Start Over You searched for: Author "Bruno Vincenzi" Remove constraint Author: "Bruno Vincenzi" Topic business.industry Remove constraint Topic: business.industry
427 results on '"Bruno Vincenzi"'

Search Results

1. The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease : an analysis by the Global Germ Cell Tumor Collaborative Group (G3)

2. Locally recurrent extraskeletal myxoid chondrosarcoma of the shoulder: a case of complete neoadjuvant radiotherapy response

3. Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case‐series analysis within the Italian Rare Cancer Network

4. Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers

5. A Staphylococcus aureus Coinfection on a COVID-19 Pneumonia in a Breast Cancer Patient

6. The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis

7. Combination of bleomycin and cisplatin as adjuvant electrochemotherapy protocol for the treatment of incompletely excised feline injection-site sarcomas: A retrospective study

8. Facing SARS-CoV-2 outbreak in immunotherapy era

9. Regression of Papillary Thyroid Cancer during Nivolumab for Renal Cell Cancer

10. Dynamic changes of Receptor activator of nuclear factor-κB expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer

11. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations : Results from a Multi-institutional European Retrospective Study

12. Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients

13. Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry

14. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

15. Abstract S01-03: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score

16. Recurrent neck myxofibrosarcoma: a case report

17. Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective

18. Type and gene location of kit mutations predict progression-free survival to first-line imatinib in gastrointestinal stromal tumors: A look into the exon

19. Immunotherapy in Hepatocellular Carcinoma

20. The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies

21. Long-term response to immuno-oncology after discontinuation for immuno-related pneumonia in metastatic renal carcinoma: a case report

22. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation

23. Upper eyelid Merkel cell carcinoma treated with neoadjuvant chemotherapy and surgical excision

24. Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma

25. Systemic therapies in advanced epithelioid haemangioendothelioma: a retrospective international case series from the World Sarcoma Network and a review of literature

26. Selinexor, a First in Class, Nuclear Export Inhibitor for the Treatment of Advanced Malignant Peripheral Nerve Sheath Tumor

27. Deep Learning Algorithm Trained with COVID-19 Pneumonia Also Identifies Immune Checkpoint Inhibitor Therapy-Related Pneumonitis

28. S-Adenosylmethionine Supplementation May Reduce Cancer-Related Fatigue: A Prospective Evaluation Using the FACIT-F Questionnaire in Colon Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy Regimens

29. COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

30. Retrospective world-wide registry on the efficacy of immune checkpoint inhibitors in alveolar soft part sarcoma : Updated results from sixty patients

31. Multiple and Concomitant Molecular Findings in a Heavily Treated Patient With EGFR-positive Lung Cancer

32. Soft Tissue Sarcomas (STS)

33. Trabectedin for patients with advanced soft tissue sarcoma: A non-interventional, retrospective, multicenter study of the italian sarcoma group

34. Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study

35. Novel drugs, familiar interactions: ciprofloxacin may increase exposure to the RET inhibitor pralsetinib

36. Efficacy of pembrolizumab in lung adenocarcinoma harboring non-V600E BRAF mutation: a case report

37. Response to: Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations

38. Recent Advances in Desmoid Tumor Therapy

39. COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management

40. Correction to: Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

41. Current and Emerging Biomarkers Predicting Bone Metastasis Development

42. Identification of Aneuploid Circulating Tumor Cells in Soft-Tissue Sarcoma Patients: A Pilot Study

43. Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?

44. Response to cabozantinib in renal cell carcinoma with cardiac metastases

45. Denosumab for cancer-related bone loss

46. Role of adjuvant imatinib dose in radically resected GIST harboring KIT exon 9 mutations

47. Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma

48. Liquid biopsy and tumor heterogeneity in metastatic solid tumors. The potentiality of blood samples

49. Clinical portrait of the SARS-CoV-2 epidemic in european patients with cancer

50. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

Catalog

Books, media, physical & digital resources